MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Becton Dickinson and Co

Uždarymo kaina

SektoriusSveikatos priežiūra

225.91 -1.35

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

225.53

Max

228.96

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-118M

303M

Pardavimai

-272M

5.2B

P/E

Sektoriaus vid.

38.627

63.778

Pelnas, tenkantis vienai akcijai

3.43

Dividendų pajamingumas

1.74

Pelno marža

5.863

Darbuotojai

70,000

EBITDA

-1.3B

453M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+19.62% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.74%

2.39%

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-6.1B

66B

Ankstesnė atidarymo kaina

227.26

Ankstesnė uždarymo kaina

225.91

Naujienos nuotaikos

By Acuity

11%

89%

18 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Becton Dickinson and Co Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-05 22:09; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

2024-11-07 12:59; UTC

Uždarbis

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

2024-11-07 12:56; UTC

Uždarbis

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

2024-08-01 11:08; UTC

Uždarbis

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

2024-06-03 11:18; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

2025-02-05 21:56; UTC

Uždarbis

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

2025-02-05 21:54; UTC

Uždarbis

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

2025-02-05 21:54; UTC

Uždarbis

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

2025-02-05 21:53; UTC

Uždarbis

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

2025-02-05 21:30; UTC

Uždarbis

Becton Dickinson 1Q Adj EPS $3.43 >BDX

2025-02-05 21:30; UTC

Uždarbis

Becton Dickinson 1Q Rev $5.2B >BDX

2025-02-05 21:30; UTC

Uždarbis

Becton Dickinson 1Q Net $303M >BDX

2025-02-05 21:30; UTC

Uždarbis

Becton Dickinson 1Q EPS $1.04 >BDX

2024-11-07 11:36; UTC

Uždarbis

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

2024-11-07 11:35; UTC

Uždarbis

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

2024-11-07 11:30; UTC

Uždarbis

Becton Dickinson 4Q EPS $1.45 >BDX

2024-11-07 11:30; UTC

Uždarbis

Becton Dickinson 4Q Adj EPS $3.81 >BDX

2024-11-07 11:30; UTC

Uždarbis

Becton Dickinson 4Q Rev $5.4B >BDX

2024-11-07 11:30; UTC

Uždarbis

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

2024-08-01 10:37; UTC

Uždarbis

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

2024-08-01 10:35; UTC

Uždarbis

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

2024-08-01 10:35; UTC

Uždarbis

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

2024-08-01 10:30; UTC

Uždarbis

Becton Dickinson 3Q EPS $1.68 >BDX

2024-08-01 10:30; UTC

Uždarbis

Becton Dickinson 3Q Net $487M >BDX

2024-08-01 10:30; UTC

Uždarbis

Becton Dickinson 3Q Adj EPS $3.50 >BDX

2024-08-01 10:30; UTC

Uždarbis

Becton Dickinson 3Q Rev $5B >BDX

2024-06-04 17:26; UTC

Įsigijimai, susijungimai, perėmimai

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

2024-06-03 15:30; UTC

Karštos akcijos

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

2024-06-03 13:26; UTC

Įsigijimai, susijungimai, perėmimai

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

2024-06-03 12:25; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Akcijų palyginimas

Kainos pokytis

Becton Dickinson and Co Prognozė

Kainos tikslas

By TipRanks

19.62% į viršų

12 mėnesių prognozė

Vidutinis 274 USD  19.62%

Aukščiausias 280 USD

Žemiausias 260 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Becton Dickinson and Co kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

227.83 / 230.0625Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

18 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.